NASDAQ:ALIM - Alimera Sciences Stock Price, Price Target & More

$1.12 0.00 (0.00 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$1.12
Today's Range$1.10 - $1.13
52-Week Range$1.00 - $1.70
Volume54,558 shs
Average Volume101,873 shs
Market Capitalization$78.38 million
P/E Ratio-3.86
Dividend YieldN/A
Beta1.72

About Alimera Sciences (NASDAQ:ALIM)

Alimera Sciences logoAlimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Receive ALIM News and Ratings via Email

Sign-up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALIM
CUSIPN/A
Phone678-990-5740

Debt

Debt-to-Equity Ratio-0.64%
Current Ratio4.07%
Quick Ratio3.91%

Price-To-Earnings

Trailing P/E Ratio-3.86
Forward P/E Ratio-18.67
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.91 million
Price / Sales2.18
Cash FlowN/A
Price / CashN/A
Book Value($0.78) per share
Price / Book-1.44

Profitability

EPS (Most Recent Fiscal Year)($0.29)
Net Income$-22,000,000.00
Net Margins-61.26%
Return on EquityN/A
Return on Assets-30.26%

Miscellaneous

Employees126
Outstanding Shares69,990,000

How to Become a New Pot Stock Millionaire

Alimera Sciences (NASDAQ:ALIM) Frequently Asked Questions

What is Alimera Sciences' stock symbol?

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

How were Alimera Sciences' earnings last quarter?

Alimera Sciences (NASDAQ:ALIM) issued its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.07. The biopharmaceutical company had revenue of $9.14 million for the quarter, compared to analysts' expectations of $9.60 million. View Alimera Sciences' Earnings History.

When is Alimera Sciences' next earnings date?

Alimera Sciences is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Alimera Sciences.

What price target have analysts set for ALIM?

3 equities research analysts have issued 12 month target prices for Alimera Sciences' stock. Their forecasts range from $3.00 to $5.00. On average, they expect Alimera Sciences' stock price to reach $4.00 in the next year. View Analyst Ratings for Alimera Sciences.

What are Wall Street analysts saying about Alimera Sciences stock?

Here are some recent quotes from research analysts about Alimera Sciences stock:
  • 1. According to Zacks Investment Research, "Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. " (4/10/2018)
  • 2. Cowen Inc analysts commented, "Adaptimmune reported Q3 financials including net loss of $1MM and a cash balance." (11/2/2017)

Who are some of Alimera Sciences' key competitors?

Who are Alimera Sciences' key executives?

Alimera Sciences' management team includes the folowing people:
  • Richard S. Eiswirth Jr., President, Chief Financial Officer (Age 47)
  • Rich Cockrell, President
  • C. Daniel Myers, Chief Executive Officer (Age 62)
  • Kenneth E. Green Ph.D., Senior Vice President, Chief Scientific Officer (Age 57)
  • David R. Holland, Senior Vice President - Sales and Marketing (Age 52)
  • Philip Ashman, Senior Vice President, European Managing Director (Age 51)
  • Mark J. Brooks, Independent Director (Age 48)
  • Brian K. Halak Ph.D., Independent Director (Age 45)
  • Peter J. Pizzo III, Independent Director (Age 49)

Has Alimera Sciences been receiving favorable news coverage?

Press coverage about ALIM stock has been trending somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alimera Sciences earned a news sentiment score of 0.14 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 45.98 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Alimera Sciences?

Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alimera Sciences' stock price today?

One share of ALIM stock can currently be purchased for approximately $1.12.

How big of a company is Alimera Sciences?

Alimera Sciences has a market capitalization of $78.38 million and generates $35.91 million in revenue each year. The biopharmaceutical company earns $-22,000,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Alimera Sciences employs 126 workers across the globe.

How can I contact Alimera Sciences?

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]


MarketBeat Community Rating for Alimera Sciences (ALIM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  179 (Vote Outperform)
Underperform Votes:  168 (Vote Underperform)
Total Votes:  347
MarketBeat's community ratings are surveys of what our community members think about Alimera Sciences and other stocks. Vote "Outperform" if you believe ALIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALIM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Alimera Sciences (NASDAQ:ALIM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Alimera Sciences in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 257.14%. The high price target for ALIM is $5.00 and the low price target for ALIM is $3.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.00$4.00$4.00$4.00
Price Target Upside: 257.14% upside233.33% upside222.58% upside185.71% upside

Alimera Sciences (NASDAQ:ALIM) Consensus Price Target History

Price Target History for Alimera Sciences (NASDAQ:ALIM)

Alimera Sciences (NASDAQ:ALIM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/22/2018HC WainwrightReiterated RatingBuy$5.00MediumView Rating Details
11/2/2017CowenReiterated RatingBuyN/AView Rating Details
4/27/2017Rodman & RenshawInitiated CoverageBuy -> Buy$4.00HighView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Alimera Sciences (NASDAQ:ALIM) Earnings History and Estimates Chart

Earnings by Quarter for Alimera Sciences (NASDAQ:ALIM)

Alimera Sciences (NASDAQ:ALIM) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.06 EPS
Next Year EPS Consensus Estimate: $0.18 EPS

Alimera Sciences (NASDAQ ALIM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.04)N/AView Earnings Details
2/28/2018Q4 2017($0.03)($0.1040)$9.60 million$9.14 millionViewListenView Earnings Details
11/1/2017Q3 2017($0.05)($0.04)$9.50 million$9.78 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.05)($0.04)$10.20 million$10.40 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.08)($0.10)$8.80 million$6.62 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.07)($0.10)$10.60 million$10.70 millionViewListenView Earnings Details
11/2/2016Q316($0.11)($0.16)$10.53 million$8.30 millionViewN/AView Earnings Details
8/3/2016Q2($0.19)($0.17)$8.42 million$3.80 millionViewN/AView Earnings Details
5/4/2016Q1($0.19)($0.22)$5.83 million$5.80 millionViewN/AView Earnings Details
3/2/2016Q4 2015($0.23)($0.24)$5.82 millionViewN/AView Earnings Details
11/5/2015Q315($0.22)($0.21)$6.96 million$6.90 millionViewN/AView Earnings Details
8/10/2015Q215($0.22)($0.25)$6.49 million$5.80 millionViewListenView Earnings Details
5/7/2015Q115($0.24)($0.27)$3.90 million$3.90 millionViewN/AView Earnings Details
3/4/2015Q414($0.16)($0.28)$5.11 million$1.70 millionViewN/AView Earnings Details
11/6/2014Q314($0.70)($0.22)$3.75 million$2.40 millionViewN/AView Earnings Details
8/7/2014Q214($0.23)($0.15)$2.70 million$2.19 millionViewN/AView Earnings Details
5/8/2014Q114($0.25)($0.20)$1.15 million$2.08 millionViewN/AView Earnings Details
2/27/2014Q413($0.29)($0.24)$0.75 million$0.94 millionViewN/AView Earnings Details
11/11/2013Q313($0.30)($0.26)$0.38 million$0.7580 millionViewN/AView Earnings Details
8/12/2013Q2 2013($0.24)($0.30)$3.00 million$0.18 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.26)($0.27)ViewN/AView Earnings Details
3/21/2013Q4 2012($0.23)($0.17)ViewN/AView Earnings Details
11/7/2012Q312($0.19)($0.17)ViewN/AView Earnings Details
8/9/2012Q2 2012($0.19)($0.15)ViewN/AView Earnings Details
5/11/2012Q1 2012($0.14)($0.14)ViewN/AView Earnings Details
3/8/2012($0.24)($0.19)ViewN/AView Earnings Details
11/3/2011($0.19)($0.21)ViewN/AView Earnings Details
8/4/2011($0.18)($0.17)ViewN/AView Earnings Details
5/5/2011($0.20)($0.15)ViewN/AView Earnings Details
2/10/2011($0.22)($0.20)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.26)($0.20)ViewN/AView Earnings Details
8/12/2010Q2 2010($0.26)($0.20)ViewN/AView Earnings Details
6/3/2010Q1 2010($0.49)($2.35)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Alimera Sciences (NASDAQ:ALIM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Alimera Sciences (NASDAQ ALIM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.70%
Institutional Ownership Percentage: 46.11%
Insider Trading History for Alimera Sciences (NASDAQ:ALIM)
Insider Trading History for Alimera Sciences (NASDAQ:ALIM)

Alimera Sciences (NASDAQ ALIM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/6/2018Armistice Capital Master FundMajor ShareholderBuy20,000$1.14$22,800.00View SEC Filing  
2/2/2018Armistice Capital, LlcMajor ShareholderBuy8,000$1.16$9,280.00View SEC Filing  
1/19/2018C. Daniel MyersCEOSell52,900$1.20$63,480.00101,511View SEC Filing  
1/19/2018Philip AshmanSVPSell25,500$1.20$30,600.0012,750View SEC Filing  
1/19/2018Richard S Eiswirth JrInsiderSell13,410$1.20$16,092.0084,779View SEC Filing  
1/17/2018C. Daniel MyersCEOSell52,900$1.23$65,067.00154,411View SEC Filing  
1/17/2018Philip AshmanSVPSell25,500$1.23$31,365.0038,250View SEC Filing  
1/17/2018Richard S Eiswirth JrInsiderSell14,494$1.23$17,827.6298,619View SEC Filing  
3/10/2017C. Daniel MyersCEOSell21,172$1.39$29,429.08180,861View SEC Filing  
9/15/2016Richard S Eiswirth JrInsiderSell51,471$1.51$77,721.2186,445View SEC Filing  
4/21/2016L.P. BavpMajor ShareholderSell478,673$2.59$1,239,763.074,477,291View SEC Filing  
12/16/2015Richard S. Eiswirth, Jr.CFOSell46,669$2.31$107,805.3934,974View SEC Filing  
12/8/2015James E FlynnInsiderBuy272,249$3.01$819,469.49View SEC Filing  
12/3/2015James E FlynnInsiderBuy243,252$3.00$729,756.00View SEC Filing  
10/30/2015James E FlynnInsiderBuy16,542$3.00$49,626.00View SEC Filing  
10/28/2015James E FlynnInsiderBuy59,342$3.00$178,026.00View SEC Filing  
10/26/2015James E FlynnInsiderBuy60,364$3.00$181,092.00View SEC Filing  
10/21/2015James E FlynnMajor ShareholderBuy160,684$3.00$482,052.00View SEC Filing  
10/20/2015James E FlynnMajor ShareholderBuy100,130$3.00$300,390.00View SEC Filing  
10/19/2015James E FlynnMajor ShareholderBuy129,226$2.92$377,339.92View SEC Filing  
10/15/2015Richard S. Eiswirth, Jr.CFOSell13,625$2.69$36,651.2534,974View SEC Filing  
10/9/2015James E FlynnInsiderBuy321,785$2.42$778,719.70View SEC Filing  
9/3/2015Calvin W RobertsDirectorBuy6,424$3.00$19,272.006,389View SEC Filing  
8/21/2015Kenneth GreenSVPSell20,000$3.29$65,800.0048,235View SEC Filing  
8/17/2015Kenneth GreenSVPSell20,000$3.90$78,000.0068,235View SEC Filing  
6/26/2015L.P. BavpMajor ShareholderSell1,024$5.00$5,120.00View SEC Filing  
6/19/2015L.P. BavpMajor ShareholderSell5,568$5.00$27,840.00View SEC Filing  
5/1/2015C. Daniel MyersCEOSell2,000$4.37$8,740.00View SEC Filing  
4/27/2015L.P. BavpMajor ShareholderSell3,114$5.02$15,632.28View SEC Filing  
4/23/2015L.P. BavpMajor ShareholderSell4,362$5.00$21,810.00View SEC Filing  
4/20/2015L.P. BavpMajor ShareholderSell30,300$5.03$152,409.00View SEC Filing  
4/15/2015L.P. BavpMajor ShareholderSell35,800$5.03$180,074.00View SEC Filing  
4/14/2015L.P. BavpMajor ShareholderSell18,400$5.01$92,184.00View SEC Filing  
4/13/2015L.P. BavpMajor ShareholderSell100$5.00$500.00View SEC Filing  
3/6/2015Richard S Eiswirth JrCFOBuy10,000$4.84$48,400.00View SEC Filing  
3/2/2015C. Daniel MyersCEOSell2,000$5.21$10,420.00View SEC Filing  
1/2/2015C. Daniel MyersCEOSell2,000$5.51$11,020.00View SEC Filing  
1/2/2015David HollandSVPSell5,000$5.56$27,800.00View SEC Filing  
12/1/2014C. Daniel MyersCEOSell2,000$5.99$11,980.00View SEC Filing  
12/1/2014David HollandSVPSell5,000$5.71$28,550.00View SEC Filing  
10/27/2014L.P. BavpMajor ShareholderSell57,918$6.34$367,200.12View SEC Filing  
10/1/2014C. Daniel MyersCEOSell2,000$5.42$10,840.00View SEC Filing  
10/1/2014David HollandSVPSell5,000$5.26$26,300.00View SEC Filing  
10/1/2014Patrick LeeMajor ShareholderSell621,191$5.42$3,366,855.22View SEC Filing  
9/30/2014Patrick LeeMajor ShareholderSell354,062$5.42$1,919,016.04View SEC Filing  
9/29/2014Patrick LeeMajor ShareholderSell240,662$5.47$1,316,421.14View SEC Filing  
9/11/2014L.P. BavpMajor ShareholderSell2,816$6.25$17,600.00View SEC Filing  
9/4/2014L.P. BavpMajor ShareholderSell39,500$6.33$250,035.00View SEC Filing  
8/29/2014L.P. BavpMajor ShareholderSell7,400$6.27$46,398.00View SEC Filing  
8/28/2014L.P. BavpMajor ShareholderSell3,000$6.27$18,810.00View SEC Filing  
8/1/2014David HollandSVPSell5,000$5.64$28,200.00View SEC Filing  
7/1/2014David HollandSVPSell5,000$6.02$30,100.00View SEC Filing  
5/1/2014David HollandSVPSell5,000$5.93$29,650.00View SEC Filing  
3/4/2014C. Daniel MyersCEOSell22,775$7.10$161,702.50View SEC Filing  
3/4/2014David HollandSVPSell10,000$6.84$68,400.00View SEC Filing  
3/4/2014Susan CaballaInsiderSell8,931$7.01$62,606.31View SEC Filing  
1/16/2014Domain Partners Vi, L.P.Major ShareholderSell296,760$6.39$1,896,296.40View SEC Filing  
7/17/2013Polaris Venture Management CoInsiderSell122,937$4.80$590,097.60View SEC Filing  
6/20/2013Domain Partners Vi, L.P.Major ShareholderSell10,516$5.01$52,685.16View SEC Filing  
6/19/2013Domain Partners Vi, L.P.Major ShareholderSell55,278$5.39$297,948.42View SEC Filing  
6/18/2013Polaris Venture Management CoInsiderSell37,063$5.44$201,622.72View SEC Filing  
6/17/2013Domain Partners Vi, L.P.Major ShareholderSell126,709$5.29$670,290.61View SEC Filing  
6/11/2013Domain Partners Vi, L.P.Major ShareholderSell5,337$5.00$26,685.00View SEC Filing  
5/17/2013David HollandSVPSell30,000$4.13$123,900.00View SEC Filing  
5/16/2013Domain Partners Vi, L.P.Major ShareholderSell44,242$4.60$203,513.20View SEC Filing  
12/13/2012Peter J Pizzo IIIDirectorBuy5,000$1.44$7,200.00View SEC Filing  
12/3/2012C. Daniel MyersCEOSell7,700$1.95$15,015.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Alimera Sciences (NASDAQ ALIM) News Headlines

Source:
DateHeadline
 Alimera Sciences (ALIM) Given Average Rating of "Strong Buy" by Analysts Alimera Sciences (ALIM) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - April 20 at 1:34 PM
HC Wainwright Analysts Give Alimera Sciences (ALIM) a $5.00 Price TargetHC Wainwright Analysts Give Alimera Sciences (ALIM) a $5.00 Price Target
www.americanbankingnews.com - April 19 at 12:16 PM
Alimera Sciences (ALIM) Raised to "Hold" at ValuEngineAlimera Sciences (ALIM) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - April 18 at 4:44 PM
Alimera Sciences (ALIM) Given a $5.00 Price Target by HC Wainwright AnalystsAlimera Sciences (ALIM) Given a $5.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 15 at 8:22 PM
Cowen Reiterates $3.00 Price Target for Alimera Sciences (ALIM)Cowen Reiterates $3.00 Price Target for Alimera Sciences (ALIM)
www.americanbankingnews.com - April 15 at 8:22 PM
Alimera Sciences (ALIM) Downgraded by ValuEngine to SellAlimera Sciences (ALIM) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - April 15 at 7:48 PM
Zacks Investment Research Upgrades Alimera Sciences (ALIM) to BuyZacks Investment Research Upgrades Alimera Sciences (ALIM) to Buy
www.americanbankingnews.com - April 10 at 8:41 AM
Alimera Sciences (ALIM) Downgraded by Zacks Investment Research to HoldAlimera Sciences (ALIM) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 2 at 4:46 PM
 Alimera Sciences (ALIM) Receives Consensus Recommendation of "Strong Buy" from Analysts Alimera Sciences (ALIM) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - April 1 at 1:26 AM
Alimera Sciences (ALIM) Raised to "Buy" at Zacks Investment ResearchAlimera Sciences (ALIM) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 30 at 4:32 PM
Zacks Investment Research Lowers Alimera Sciences (ALIM) to HoldZacks Investment Research Lowers Alimera Sciences (ALIM) to Hold
www.americanbankingnews.com - March 23 at 4:34 PM
Alimera Sciences (ALIM) Raised to Buy at Zacks Investment ResearchAlimera Sciences (ALIM) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - March 22 at 4:32 PM
Edited Transcript of ALIM earnings conference call or presentation 1-Mar-18 2:00pm GMTEdited Transcript of ALIM earnings conference call or presentation 1-Mar-18 2:00pm GMT
finance.yahoo.com - March 18 at 10:01 AM
Stonepine Capital Management LLC Grows Position in Alimera Sciences Inc (ALIM)Stonepine Capital Management LLC Grows Position in Alimera Sciences Inc (ALIM)
www.americanbankingnews.com - March 6 at 10:02 AM
Global Diabetic Retinopathy Market Anticipated Growth By Increasing Incidence of Ophthalmic Complications in Diabetic PatientsGlobal Diabetic Retinopathy Market Anticipated Growth By Increasing Incidence of Ophthalmic Complications in Diabetic Patients
www.marketwatch.com - March 5 at 10:42 AM
Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 2 at 4:22 PM
Alimera Sciences (ALIM) Posts Quarterly  Earnings Results, Misses Expectations By $0.07 EPSAlimera Sciences (ALIM) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS
www.americanbankingnews.com - March 1 at 11:18 AM
Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial ResultsAlimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 1 at 9:41 AM
Alimera Sciences, Inc. to Host Earnings CallAlimera Sciences, Inc. to Host Earnings Call
finance.yahoo.com - March 1 at 9:41 AM
Alimera Sciences to Present at the 38th Annual Cowen & Co. Health Care ConferenceAlimera Sciences to Present at the 38th Annual Cowen & Co. Health Care Conference
finance.yahoo.com - February 27 at 10:15 AM
Head to Head Comparison: Argos Therapeutics (ARGS) versus Alimera Sciences (ALIM)Head to Head Comparison: Argos Therapeutics (ARGS) versus Alimera Sciences (ALIM)
www.americanbankingnews.com - February 25 at 1:10 AM
Alimera Sciences (ALIM) Scheduled to Post Quarterly Earnings on TuesdayAlimera Sciences (ALIM) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 20 at 3:46 AM
Alimera Sciences to Report Fourth Quarter and Full Year 2017 Results on February 28, 2018Alimera Sciences to Report Fourth Quarter and Full Year 2017 Results on February 28, 2018
finance.yahoo.com - February 14 at 3:24 PM
Alimera Sciences, Inc. (ALIM) Major Shareholder Armistice Capital Master Fund Buys 20,000 SharesAlimera Sciences, Inc. (ALIM) Major Shareholder Armistice Capital Master Fund Buys 20,000 Shares
www.americanbankingnews.com - February 9 at 9:08 PM
Alimera Sciences (ALIM) Receives "Buy" Rating from HC WainwrightAlimera Sciences (ALIM) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - January 22 at 11:54 PM
Insider Selling: Alimera Sciences, Inc. (ALIM) SVP Sells 25,500 Shares of StockInsider Selling: Alimera Sciences, Inc. (ALIM) SVP Sells 25,500 Shares of Stock
www.americanbankingnews.com - January 19 at 10:50 PM
Insider Selling: Alimera Sciences, Inc. (ALIM) Insider Sells 13,410 Shares of StockInsider Selling: Alimera Sciences, Inc. (ALIM) Insider Sells 13,410 Shares of Stock
www.americanbankingnews.com - January 19 at 10:50 PM
Alimera Sciences, Inc. (ALIM) CEO C. Daniel Myers Sells 52,900 SharesAlimera Sciences, Inc. (ALIM) CEO C. Daniel Myers Sells 52,900 Shares
www.americanbankingnews.com - January 19 at 10:30 PM
Alimera Sciences, Inc. (ALIM) Insider Sells $17,827.62 in StockAlimera Sciences, Inc. (ALIM) Insider Sells $17,827.62 in Stock
www.americanbankingnews.com - January 18 at 8:30 PM
Philip Ashman Sells 25,500 Shares of Alimera Sciences, Inc. (ALIM) StockPhilip Ashman Sells 25,500 Shares of Alimera Sciences, Inc. (ALIM) Stock
www.americanbankingnews.com - January 18 at 8:30 PM
Insider Selling: Alimera Sciences, Inc. (ALIM) CEO Sells 52,900 Shares of StockInsider Selling: Alimera Sciences, Inc. (ALIM) CEO Sells 52,900 Shares of Stock
www.americanbankingnews.com - January 18 at 8:00 PM
Strongbridge Biopharma (SBBP) vs. Alimera Sciences (ALIM) Critical ReviewStrongbridge Biopharma (SBBP) vs. Alimera Sciences (ALIM) Critical Review
www.americanbankingnews.com - January 10 at 8:02 AM
Alimera Sciences (ALIM) Upgraded to "Hold" by Zacks Investment ResearchAlimera Sciences (ALIM) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - January 8 at 9:26 PM
BRIEF-Alimera Sciences Enters Into $40 Mln Term Loan Agreement With Solar CapitalBRIEF-Alimera Sciences Enters Into $40 Mln Term Loan Agreement With Solar Capital
www.reuters.com - January 8 at 3:43 PM
Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital - GlobeNewswire (press release)Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital - GlobeNewswire (press release)
globenewswire.com - January 8 at 8:33 AM
Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar CapitalAlimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital
finance.yahoo.com - January 8 at 8:33 AM
Alimera Sciences (ALIM) Announces Acceptance of Filing to Obtain Approval for ILUVIEN Non-Infectious Posterior ... - StreetInsider.comAlimera Sciences (ALIM) Announces Acceptance of Filing to Obtain Approval for ILUVIEN Non-Infectious Posterior ... - StreetInsider.com
www.streetinsider.com - January 5 at 3:40 PM
Alimera Sciences (ALIM) Announces Acceptance of Filing to Obtain Approval for ILUVIEN Non-Infectious Posterior Uveitis Indication in EuropeAlimera Sciences (ALIM) Announces Acceptance of Filing to Obtain Approval for ILUVIEN Non-Infectious Posterior Uveitis Indication in Europe
www.streetinsider.com - January 4 at 3:38 PM
Alimera Sciences Receives Acceptance of Filing to Obtain Approval for ILUVIEN® Non-Infectious Posterior Uveitis Indication in EuropeAlimera Sciences Receives Acceptance of Filing to Obtain Approval for ILUVIEN® Non-Infectious Posterior Uveitis Indication in Europe
finance.yahoo.com - January 4 at 11:14 AM
Alimera Sciences (ALIM) Raised to Sell at ValuEngineAlimera Sciences (ALIM) Raised to Sell at ValuEngine
www.americanbankingnews.com - December 31 at 2:58 PM
ETFs with exposure to Alimera Sciences, Inc. : December 18, 2017ETFs with exposure to Alimera Sciences, Inc. : December 18, 2017
finance.yahoo.com - December 18 at 3:37 PM
Alimera Sciences Announces Patients Now Being Treated With ILUVIEN® In IrelandAlimera Sciences Announces Patients Now Being Treated With ILUVIEN® In Ireland
finance.yahoo.com - December 11 at 12:04 PM
ETFs with exposure to Alimera Sciences, Inc. : December 8, 2017ETFs with exposure to Alimera Sciences, Inc. : December 8, 2017
finance.yahoo.com - December 8 at 3:37 PM
Head to Head Analysis: Alimera Sciences (ALIM) and Novus Therapeutics (NVUS)Head to Head Analysis: Alimera Sciences (ALIM) and Novus Therapeutics (NVUS)
www.americanbankingnews.com - December 7 at 1:16 PM
Reviewing Fortress Biotech (FBIO) & Alimera Sciences (ALIM)Reviewing Fortress Biotech (FBIO) & Alimera Sciences (ALIM)
www.americanbankingnews.com - December 4 at 7:39 PM
Alimera Sciences (ALIM) Downgraded by ValuEngine to Strong SellAlimera Sciences (ALIM) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - December 3 at 6:30 AM
Alimera Sciences to Present at the 10th Annual LD Micro ConferenceAlimera Sciences to Present at the 10th Annual LD Micro Conference
finance.yahoo.com - November 28 at 3:36 PM
Alimera Sciences, Inc. (ALIM) Cut to Sell at Zacks Investment ResearchAlimera Sciences, Inc. (ALIM) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - November 27 at 5:28 PM
Alimera Sciences, Inc. (ALIM) Earns Buy Rating from HC WainwrightAlimera Sciences, Inc. (ALIM) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - November 22 at 4:26 PM
ETFs with exposure to Alimera Sciences, Inc. : November 21, 2017ETFs with exposure to Alimera Sciences, Inc. : November 21, 2017
finance.yahoo.com - November 21 at 4:15 PM

SEC Filings

Alimera Sciences (NASDAQ:ALIM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Alimera Sciences (NASDAQ:ALIM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Alimera Sciences (NASDAQ ALIM) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.